10x Genomics (TXG) Research & Development (2018 - 2026)

10x Genomics (TXG) has 9 years of Research & Development data on file, last reported at $56.8 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 11.52% year-over-year to $56.8 million; the trailing twelve-month figure through Mar 2026 stood at $231.2 million (down 11.17% YoY), and the FY2025 full-year result was $238.6 million, down 9.85% from the prior year.
• Research & Development advanced to $56.8 million in Q1 2026, from $56.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $71.5 million in Q2 2023 to a low of $56.0 million in Q4 2025.
• A 5-year average of $64.5 million and a median of $65.3 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 52.99% in 2022 and slipped 16.42% in 2025, its largest moves.
• Tracing TXG's Research & Development over 5 years: stood at $63.6 million in 2022, then advanced by 2.6% to $65.3 million in 2023, then rose by 2.61% to $67.0 million in 2024, then retreated by 16.42% to $56.0 million in 2025, then grew by 1.57% to $56.8 million in 2026.
• Business Quant data shows TXG's Research & Development at $56.8 million in Q1 2026, $56.0 million in Q4 2025, and $57.2 million in Q3 2025.